Overview

RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT Lymphoma

Status:
Not yet recruiting

Trial end date:
2027-10-06

Target enrollment:

Participant gender:

Summary

This project proposes to establish a prospective, multicenter, randomized, controlled clinical study to compare the safety and efficacy of Intralesional Rituximab Injection versus Involved Site Radiation Therapy for the treatment of primary ocular adnexal MALT lymphoma. The aim is to provide high-level clinical evidence for the treatment of ocular adnexal MALT lymphoma and to offer patients treatment options that have fewer complications and comparable therapeutic effects.

Phase:

N/A

Details

Lead Sponsor:

Zhongshan Ophthalmic Center, Sun Yat-sen University

Treatments:

Rituximab